Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience
Metastatic bladder cancer has poor overall survival. Though systemic therapies have shown to improve overall survival, real-world studies have shown that more than half of the patients do not receive any systemic therapy, while only around 15–20% receive second-line therapy. Even in patients receivi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294221000241 |